致密乳腺且乳腺癌风险不同的女性补充超声筛查表现:乳腺癌症监测联盟结果
该回顾性观察研究纳入2014年1月至2020年10月三个BCSC登记处24个放射机构的34 791次致密乳腺补充超声筛查,评估不同预估乳腺癌风险水平下的癌症检出率、假阳性活检推荐率和活检阳性预测值(PPV3)。高风险组6年晚期乳腺癌风险的癌症检出率、假阳性活检推荐率和PPV3均高于低或平均风险组,5年浸润性乳腺癌风险呈现相似模式。
要点
- 致密乳腺补充超声筛查总体癌症检出率为每1000次检查2.0(95%CI 1.6, 2.4),总体PPV3为6.9%(67/975;95%CI 5.3, 8.9)。
- 6年晚期乳腺癌高风险组癌症检出率为每1000次5.5(95%CI 3.5, 8.6),高于低或平均风险组的每1000次1.3(95%CI 1.0, 1.8)(P=.003)。
- 6年晚期乳腺癌高风险组假阳性活检推荐率为每1000次37.0(95%CI 28.2, 48.4),高于低或平均风险组的每1000次28.1(95%CI 20.9, 37.8)(P=.04)。
核心结论
- 补充超声筛查的癌症检出率和PPV3随预估晚期及浸润性乳腺癌风险升高而增加。
研究设计与样本
- 回顾性观察研究,使用三个乳腺癌症监测联盟(BCSC)登记处24个放射机构2014年1月至2020年10月的超声筛查数据,纳入26 489例女性患者的34 791次筛查(筛查时平均年龄53.9岁±9.0[SD]),采用BCSC风险预测模型评估6年晚期乳腺癌风险和5年浸润性乳腺癌风险。
诊断标准与关键数值
- 总体癌症检出率为每1000次检查2.0(95%CI 1.6, 2.4);6年晚期乳腺癌高风险组每1000次5.5(95%CI 3.5, 8.6)vs低或平均风险组每1000次1.3(95%CI 1.0, 1.8)(P=.003)。总体假阳性活检推荐率为每1000次29.6(95%CI 22.6, 38.6);高风险组每1000次37.0(95%CI 28.2, 48.4)vs低或平均风险组每1000次28.1(95%CI 20.9, 37.8)(P=.04)。总体PPV3为6.9%(67/975;95%CI 5.3, 8.9);高风险组15.0%(15/100;95%CI 9.9, 22.2)vs低或平均风险组4.9%(30/615;95%CI 3.3, 7.2)(P=.01)。5年浸润性乳腺癌风险分析呈现相似模式。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background It is unclear whether breast US screening outcomes for women with dense breasts vary with levels of breast cancer risk. Purpose To evaluate US screening outcomes for female patients with dense breasts and different estimated breast cancer risk levels. Materials and Methods This retrospective observational study used data from US screening examinations in female patients with heterogeneously or extremely dense breasts conducted from January 2014 to October 2020 at 24 radiology facilities within three Breast Cancer Surveillance Consortium (BCSC) registries. The primary outcomes were the cancer detection rate, false-positive biopsy recommendation rate, and positive predictive value of biopsies performed (PPV3). Risk classification of participants was performed using established BCSC risk prediction models of estimated 6-year advanced breast cancer risk and 5-year invasive breast cancer risk. Differences in high- versus low- or average-risk categories were assessed using a generalized linear model. Results In total, 34 791 US screening examinations from 26 489 female patients (mean age at screening, 53.9 years ± 9.0 [SD]) were included. The overall cancer detection rate per 1000 examinations was 2.0 (95% CI: 1.6, 2.4) and was higher in patients with high versus low or average risk of 6-year advanced breast cancer (5.5 [95% CI: 3.5, 8.6] vs 1.3 [95% CI: 1.0, 1.8], respectively; P = .003). The overall false-positive biopsy recommendation rate per 1000 examinations was 29.6 (95% CI: 22.6, 38.6) and was higher in patients with high versus low or average 6-year advanced breast cancer risk (37.0 [95% CI: 28.2, 48.4] vs 28.1 [95% CI: 20.9, 37.8], respectively; P = .04). The overall PPV3 was 6.9% (67 of 975; 95% CI: 5.3, 8.9) and was higher in patients with high versus low or average 6-year advanced cancer risk (15.0% [15 of 100; 95% CI: 9.9, 22.2] vs 4.9% [30 of 615; 95% CI: 3.3, 7.2]; P = .01). Similar patterns in outcomes were observed by 5-year invasive breast cancer risk. Conclusion The cancer detection rate and PPV3 of supplemental US screening increased with the estimated risk of advanced and invasive breast cancer. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Helbich and Kapetas in this issue.
引用
- Sprague BL, Ichikawa L, Eavey J, et al. Performance of Supplemental US Screening in Women with Dense Breasts and Varying Breast Cancer Risk: Results from the Breast Cancer Surveillance Consortium. Radiology. 2024. PMID: 39105648. doi:10.1148/radiol.232380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。